AstraZeneca Atacand comparative efficacy
FDA's Cardiovascular & Renal Drugs Advisory Committee will review Atacand (candesartan) for proposed comparative efficacy claim to Merck's Cozaar (losartan) in treatment of hypertension on July 18. The sNDA (20-338/S-015) is based on AstraZeneca's CLAIM studies conducted in 1,200 patients. The meeting will take place at the Holiday Inn-Bethesda, Md., beginning at 8 a.m. [To sign up for a 1webcast, go to FDAAdvisoryCommittee.com]....
You may also be interested in...
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.